CINGWNasdaqPharmaceutical PreparationsUS GAAP · USD

Cingulate Inc.

Cingulate Inc. is a clinical-stage pharmaceutical company developing differentiated prescription therapies, with its lead program CTx-1301 aimed at ADHD. The company is focused on advancing its pipeline through clinical development, regulatory filing, and eventual commercialization via partnerships or outsourced sales infrastructure.

Kysy yhtiöstä
Liikevoitto (EBIT)−19,9milj. USD
−27,4 %v/v
Nettotulos−22,4milj. USD
−35,6 %v/v
Vapaa kassavirta−17,4milj. USD
+6,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−25−20−15−10−50milj. USD2020: EBIT −7,1 milj. USD20202021: EBIT −21 milj. USD20212022: EBIT −18 milj. USD20222023: EBIT −23 milj. USD20232024: EBIT −16 milj. USD20242025: EBIT −20 milj. USD2025−20
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Cingulate Inc.

Liiketoiminta

Osuus liikevaihdosta
Lead drug candidate development70 %

Clinical development, manufacturing, and regulatory work for CTx-1301 and related pipeline assets.

Pipeline expansion and in-licensing15 %

Evaluation of new products, product candidates, and acquisitions to broaden the portfolio.

Commercialization partnerships10 %

Potential licensing and fee-for-service commercialization support for approved products.

Grant-funded development programs5 %

Externally funded clinical and manufacturing work, including CTx-2103 support.

Asiakkaat

Cingulate does not yet sell commercial products, so its near-term counterparties are primarily clinical research organizations, manufacturers, regulators, and potential licensing partners. If approved, its end customers would be physicians, patients, and payers in the ADHD market, with commercialization potentially handled through partners rather than a large internal sales force.

Pharmaceutical licensing partners

Companies that may license CTx-1301 in the U.S. or internationally to commercialize the asset.

Clinical development vendors

CROs, investigators, and manufacturers that provide trial execution, supply, and testing services.

Regulatory agencies

FDA and comparable authorities that review the NDA and determine approval timing.

Future ADHD prescribers and patients

Physicians and patients who would use the product if approved, driving eventual product demand.

Strategia

Cingulate’s strategy is to complete development of CTx-1301, file the NDA, and secure a pharmaceutical partner or outsourced commercialization model. It is also trying to broaden the pipeline through in-licensing, acquisitions, and grant- or partner-supported development to reduce dependence on a single asset.

File the NDA for CTx-1301Lyhyt aikaväli

Regulatory submission is the key milestone needed to move the lead asset toward approval and value creation.

Secure a strategic pharmaceutical partnershipLyhyt aikaväli

A partner can provide commercialization reach and reduce the need for Cingulate to build costly sales infrastructure.

Fund pipeline and commercialization needsLyhyt aikaväli

The company needs additional capital to continue development and support launch activities if approval is obtained.

Broaden the product pipelineKeskipitkä aikaväli

Adding assets through in-licensing or acquisition can diversify risk beyond a single lead program.

Maantiede

Cingulate is headquartered in the United States and its current development, regulatory, and commercialization planning is centered there. The company also states it may seek international licensing for CTx-1301, but it has not disclosed meaningful country revenue because it has not generated product sales.

Riskit

Cingulate is a pre-revenue clinical-stage company, so its business depends on successful trials, regulatory approval, and access to capital. The company also faces execution risk around manufacturing, commercialization outsourcing, and partner selection, while broader pharmaceutical risks include patent disputes, FDA delays, and inability to retain key personnel.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical and regulatory failure risk2Commercialization execution risk3Manufacturing and supply chain risk4Key personnel retention risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern and financing riskVaikutus: Kriittinen

    The company has no product revenue and expects to need additional capital to fund operations and commercialization.

    Kohdistuu: Cash runway into fourth quarter 2025 under current plan

  2. Clinical and regulatory failure riskVaikutus: KorkeaTodennäköisyys: Korkea

    CTx-1301 and other candidates may not achieve successful trial outcomes or FDA approval.

    Kohdistuu: Lead asset NDA timing and approval pathway

  3. Commercialization execution riskVaikutus: KorkeaTodennäköisyys: Matala

    The company may rely on partners or outsourced providers for marketing, sales, market access, and distribution.

    Kohdistuu: Indegene MSA and future licensing arrangements

  4. Manufacturing and supply chain riskVaikutus: KeskitasoTodennäköisyys: Korkea

    Clinical supply and commercial-scale manufacturing timing can affect trial progress and launch readiness.

    Kohdistuu: CTx-1301 and CTx-2103 development

  5. Key personnel retention riskVaikutus: KeskitasoTodennäköisyys: Korkea

    A small development-stage company depends heavily on a limited management and scientific team.

    Kohdistuu: Management and R&D execution

Kysy Clarifolta: Cingulate Inc.

Kirjanpito

Harkinnanvaraiset erät
Research and development expense accruals

External development costs are recognized based on vendor progress, which requires judgment and can shift quarterly expense timing.

Vaikutus: Affects operating loss comparability quarter to quarter

Going-concern assessment

Management states substantial doubt about the company’s ability to continue as a going concern without additional capital.

Vaikutus: Important for liquidity and financial statement interpretation

Grant accounting and contingent royalty obligation

The $3 million grant for CTx-2103 and contingent royalty payments create specific funding and future obligation considerations.

Vaikutus: Affects cash flow, liabilities, and future commercialization economics

Future collaboration and license revenue recognition

Any future partnership or licensing deal could create upfront, milestone, or service revenue with complex timing.

Vaikutus: Could materially change reported revenue once commercialization begins

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Minerva Neurosciences, Inc.

NERV · Pharmaceutical Preparations

Actuate Therapeutics, Inc

ACTU · Pharmaceutical Preparations

CTT Pharmaceutical Holdings, Inc.

CTTH · Pharmaceutical Preparations

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

LB Pharmaceuticals Inc

LBRX · Pharmaceutical Preparations

Päivitetty: 24.9.2026